Abstract
Corticosteroids play an essential role in the treatment of many inflammatory autoimmune diseases and often are the first line treatment option for rapid clinical response. The significant therapeutic effects, however, are often accompanied by adverse side effects. The most common and serious complication is glucocorticoid-induced osteoporosis, remaining a potentially preventable but often poorly treated side effect. Although a rarer complication, osteonecrosis is more debilitating and occurs most commonly in patients taking higher doses of corticosteroids. Metabolic and endocrine side effects, including hyperglycemia and diabetes mellitus, are potential complications, even at low dosing. Hypothalamic-pituitary adrenal suppression with secondary adrenal insufficiency can be observed more rapidly at higher dosing or longer treatment duration, although has been observed with shorter duration and lower dosing of corticosteroids as well. Corticosteroid treatment may also induce or exacerbate psychiatric disorders such as anxiety, depression, and, less commonly, psychosis. Cardiovascular side effects may also occur with corticosteroid use including hypertension, dyslipidemia and atherosclerosis. Perhaps most notably and well-described is the increased susceptibility to infections accompanying corticosteroid use, thought to occur largely through several alterations in host defenses. Ophthalmologic side effects including cataract development and increased intraocular pressure require close monitoring in the setting of long-term glucocorticoid use. In addition, several adverse GI side effects including reflux disease, gastritis and peptic ulcers have been noted with corticosteroid use. Strategies for prevention of these adverse events remain an important component during corticosteroid management.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420–6.
Barnes P. How corticosteroids control inflammation: Quintiles Prize Lecture. Br J Pharmacol. 2006;148:245–54.
Rhen T, Cidlowski J. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med. 2005;353:1711–23.
Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007;275:109.
Maricic M. Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2011;37:415–31.
Saag KG. Bone safety of low-dose glucocorticoids in rheumatic diseases. Ann N Y Acad Sci. 2014;1318:55–64.
Saag KG, Gehlbach SH, Curtis JR, et al. Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol. 2006;33:1651–7.
Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006;17:105–8.
Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73–81.
Grossman J, Gordon R, Ranganath V, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–26.
Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41:183–90.
Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011;78:748–56.
Warrington TP, Bostick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81:1361–7.
Kenna HA, Poon AW, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011;65:549–60.
Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513–9.
El-Shaboury AH, Hayes TM. Hyperlipidemia in asthmatic patients receiving long-term steroid therapy. Br Med J. 1973;2:85–6.
Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med. 1988;85:632–8.
Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31:1213–24.
Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumaonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34.
Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754–64.
Jick SS, Lieberman ES, Rahman EU, Choi HK, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19–26.
Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13.
Townsend HB, Saag KG. Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol. 2004;22 Suppl 35:S77–82.
Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8–14.
Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmol. 1980;98:1773–7.
Garbe E, LeLorier J, Biobin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 1997;350:979–82.
Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–40.
Garcia-Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3:98–101.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Townsend, H.B., Turkiewicz, A.M., Whittier, X.A. (2016). Systemic Corticosteroids. In: Sami, N. (eds) Autoimmune Bullous Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26728-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-26728-9_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26726-5
Online ISBN: 978-3-319-26728-9
eBook Packages: MedicineMedicine (R0)